Clinical Programs

Therapix Biosciences signed a license agreement with Ramot for a novel technology for using ultra-low THC dosages for treating mild cognitive impairment
Therapix is using technology developed at the Faculty of Medicine of Tel Aviv University, in the context of the Company’s Brain-Bright Program

Therapix, a specialty pharma company engaged in the development of cannabinoid-based prescribed drugs, announced on February 15th, 2016 that it has entered into a definitive agreement with Ramot, Tel Aviv University’s technology transfer organization, for a license to research, develop, use and commercialize a technology for methods of treatment of deterioration in cognitive functioning, through the administration of ultralow dosages of THC.

Recent studies conducted by Prof. Sarne from the Tel-Aviv University, have shown that treatment with considerably low dosages (relative to standard dosages) of THC, achieved improvement and prevention of cognitive deterioration in animals. 

The Company’s BrainBright Program focuses on a wide market of pre-Alzheimer’s disorders and the mild cognitive impairment (MCI), with an emphasis on age-dependent deterioration in cognitive functioning. Therapix is developing a unique prescription drug, based on a synthetic cannabinoid (Dronabinol) which has been approved for medicinal use by the FDA, for delaying the phenomenon of memory loss and preventing deterioration to possibly the early stages of Alzeimer’s disease.

The Company believes that the development & commercialization of the drug could be accelerated by taking an abbreviated regulatory path (505(b)(2)), while using the existing safety data from the FDA.

Dr. Elran Haber, the Company’s CEO, stated that “we are delighted by the signing of the definitive agreement with Ramot and strengthening the collaboration with the TelAviv University, an agreement that will enable us to accelerate the development processes of Therapix' novel program for using an ultra-low dose of THC for treatment of MCI. The Company intends to complete the necessary preparations for commencing clinical trials in humans shortly. The company is repositioning an FDA-approved drug in order to address an unmet medical need. Since the safety-profile of the drug is well known and because we utilize a significantly lower dose of THC through our proprietary drug delivery formulations, we believe we can shorten the time to commence human clinical trials". 






Dr. Elisha Nathan, Director Business Development at Ramot stated that “Therapix is the right partner for taking the next steps in the development of the novel technology that originates from research of the THC conducted at the laboratory of Prof. Sarne. We believe that Therapix can considerably contribute to the technology’s maturation into a medical solution that will address the prevention of cognitive impairment (MCI)”. 

About Therapix

Therapix Biosciences Ltd. (TASE, OTCQB: THXBY) is a specialty pharmaceutical company. The company is focused on the development of cannabinoid based pharmaceuticals. Therapix' ADR is listed on the OTCQB market; and recently brought in new key investors. The company intends to take proactive steps to raise awareness of the company and its activity, both clinical and commercial, in the US capital market. The Company focuses on the creation and expansion of a portfolio of technologies and assets in the field of treatments based on an FDA-approved cannabinoids (active compounds in the cannabis plant) drugs. Therapix is currently developing two clinical programs utilizing cannabinoid-based drugs for the treatment of Tourette's syndrome (under an orphan drug designation) and mild cognitive impairment (MCI).

About Ramot at Tel-Aviv University Ltd.

Ramot is the Tel-Aviv University's technology transfer company. The company specializes in the protection and commercialization of inventions, discoveries and technologies created in the context of academic research. 

Tel-Aviv University is currently considered one of the leading and most prestigious academic and research centers in the world, with an annual investment in research and development exceeding $180 million.

Through Ramot’s activity, the University has registered thousands of patents. Today, there are around 600 active patent families for commercialization, 30% of which have already been commercialized through international and start-up companies.

For additional information see: